Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
“Tactics”? A “Fezzy pause” - is That’s what you think is required to resume ECOR’s ascent?
How About DATA? Hmmm? This company’s future is being decided in Spain & Pennsylvania
Right Now. If interim data -out soon is positive ECOR can secure an EUA for more severe and common respiratory disease asthma has a 0.9 % incidence in COVID 19 while ARDS a 9.4% incidence. Demonstrate positive respiratory data in Spain and/or Pa. and ECOR can thrive inspire of poor tactics and an onslaught
of posts from me.
( without it - all the tactics and silence in the world won’t help).
ECOR - Philips Healthcare Target - Dutch Vagal Stimulation study uses Philips technology - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6879675/#!po=70.7547 Philips just sold Consumer division to boost bolt-on medical acquisitions.
ECOR FOX/CBS PR- Why? ahead of 2nd EUA? M&A? Monday Monday
ECOR “Philips is seeking to expand our M&A team in Cambridge to support our inorganic growth strategy as we continue to transform and focus our businesses, as a global leader in Health Technology“
https://onmogul.com/jobs/m-a-senior-manager-efb19d36-6abb-4f65-bd3a-0b0c599812c5
ECOR- Problem with Implanted Vagal Stimulus leads to Class 1 (worst) Recall. Gammacore is safer-
May have OTC version.
https://www.medtechdive.com/news/livanova-recalls-vagus-nerve-implant-amid-reset-problems/569588/
ECOR -“Jacksonville doctor creates device that could help COVID-19 patients” https://www.google.com/amp/s/www.actionnewsjax.com/news/local/duval-county/jacksonville-doctor-creates-device-help-covid-19-patients/VFA5TP74VRCKLKLDK65VEZVHCU/%3foutputType=amp
ECOR - perfect Philips Target- sold off consumer division to concentrate on MedTech M&A : https://www.google.com/amp/s/www.evaluate.com/node/15505/amp
ECOR-Philips M&A fit- “Philips' diagnosis and treatment business saw a 9% sales drop in the second quarter of 2020 as COVID-19 drove many hospitals to idle new equipment installations and elective medical procedures—but it's not all bad news for the medtech giant. The company's Connected Care divisions saw a 14% sales increase boosted by demand for ventilators and remote patient monitoring systems, while incoming orders grew 27%. ”
https://www.fiercepharma.com/pharma/coronavirus-tracker-hydroxychloroquine-fails-va-study-fda-approves-at-home-sample-collection
Philips has an electrical medicine interest https://www.google.com/amp/s/www.usa.philips.com/c-p/PR3841_00.amp/pulserelief-multi-area-drug-free-pain-therapy and is a likely acquirer of
ECOR.
.
ECOR on CBS FOX “Jacksonville doctor creates device to help COVID-19 patients” “It’s called the Gamma Core Sapphire CV device. It’s designed to stop pain signals from reaching the brain, originally approved to treat headaches and migraines. During the pandemic, they found success with coronavirus patients.
“The virus itself is bad,” Dr. Staats said. “But part of the reason why the virus is bad is because it activates the immune response in a really robust way. Overly robust to the point the body starts attacking itself.”
He said this device is used to calm the immune system with coronavirus patients.”
https://www.google.com/amp/s/www.actionnewsjax.com/news/local/duval-county/jacksonville-doctor-creates-device-help-covid-19-patients/VFA5TP74VRCKLKLDK65VEZVHCU/%3foutputType=amp
2nd ECOR Respiratory RCT -SAVIOR- in Spain - “One neurotech firm taking a leading role in this effort is electroCore, Inc., the Basking Ridge, NJ bioelectronic medicine company. The company announced that an investigator-initiated, randomized, controlled clinical trial of nVNS therapy has commenced enrolling COVID-19 patients in Spain. The trial, “Prospective, Randomized, Controlled Study to Evaluate the Effect of Non-Invasive Electrical Vagus Nerve Stimulation on Respiratory Symptoms due to COVID-19 (SAVIOR),” is designed to assess the ability of nVNS to decrease the number of hospitalized COVID-19 patients requiring use of a ventilator.” https://www.globenewswire.com/news-release/2020/04/27/2022434/0/en/electroCore-Provides-Update-on-COVID-19-Clinical-Initiatives.html
From ECOR and Allegheny Health Network- RCT with“primary objective is to reduce initiation of mechanical ventilation in patients with CoViD-19 compared to the control group. Secondary objectives are to evaluate cytokine trends/prevent cytokine storms, evaluate supplemental oxygen requirements, decrease mortality of CoViD-19 patients and to delay the onset of mechanical ventilation.” Via Gammacore - Estimated Primary Completion Date :
September 1, 2020 -Interim readout may lead to Expanded Respiratory EUA
https://clinicaltrials.gov/ct2/show/NCT04382391?term=Electrocore&draw=4&rank=23
Maybe my AM posts helped ECOR rise on No news. Did you know ARDS is >10x more common than
Asthma In COVID 19? Read and Learn.
ARDS - 9.4% prevalence in COVID sciencedirect.com/science/a... Asthma 0.9% in COVID ncbi.nlm.nih.gov/pmc/articl...
ECOR hit $3.30 on Asthma - So ECOR ARDS EUA will pop it to $10+ then JMP price target.
“We postulate that neuromodulation (Vagus Nerve Stimulation) could work similarly to TNF-a inhibitors (Humira) to interrupt chronic inflammation, and potentially treat inflammatory skin disease.” https://link.springer.com/article/10.1007/s13555-018-0227-4 ECOR
ECOR “Koopman et al. findings - demonstrate significantly reduced serum levels of pro-inflammatory cytokines TNF, IL-1ß, and IL-6 after 42 days of VNS in humans” ARDS EUA coming.
https://link.springer.com/article/10.1007/s13555-018-0227-4
ECOR AH- Stay Tuned.
The failure of Actemra and Kevzara in ARDS raises the reward of an
ECOR EUA - which will seem so obvious once it’s granted and its price zooms out of reach.
ECOR PT is $29 at JMP - that’s based on treatment of ARDS by Gammacore- but doesn't take into consideration OTC treatment of more mild COVID19 symptoms.
ECOR ARDS EUA leak? 5.5M ECOR shares before close on no news
ECOR EUA for ARDS will be based on TNFa Reduction And IL10 elevation- coming soon as all patients will be enrolled in trial by next week - EUA on interim read -as in Asthma.
ECOR - Cytokines and the immunomodulatory function of the vagus nerve “Stimulation of the vagus nerve attenuates cytokine production and improves survival in experimental sepsis, haemorrhagic shock, ischaemia–reperfusion injury, and other conditions of cytokine excess and research is now underway in developing new and novel therapeutics aimed at stimulating the vagus nerve either directly or targeting specific components of the pathway.” bjanaesthesia.org.uk/400.jsp
ECOR - So most effective mode of Vagal stimulation, with potency that reduces inflammatory TNF-a and elevates anti-inflammatory IL-10, and safety that is being considered for an Over the Counter version. Bullish.
ECOR - no Auricular is NOT a more potent approach to Vagal Stimulation than Cervical. -Utilizes a minor branch of Vagus Nerve so just the opposite - https://thedoctorskitchen.com/wp-content/uploads/2020/02/A-review-of-vagus-nerve-stimulation-as-a-therapeutic-intervention.pdf ECOR has Best approach.
ECOR -Is Vagal Stimulation via the Ears more potent than via the Neck?
AKRXQ getting close to Aug D day without Equity Committee - Not Approved
AKRXQ Equity Committee Approval
ECOR “parameters selectively lowered serum TNF levels, as compared to sham-stimulated mice. In addition, serum levels of the anti-inflammatory cytokine interleukin-10 (IL-10) were significantly increased by select parameters of electrical stimulation” https://scholar.google.com/scholar?as_ylo=2016&q=Cytokine+Reduction+by+vagal+stimulation&hl=en&as_sdt=0,33#d=gs_qabs&u=%23p%3DnZEwRLIsi6AJ IL-10 has been shown to be protective against Coronaviral Encephalitis.
BRRGF BGBIO
in addition to COVID, Bemcentinib studied in Solid Cancer- NSCLC, GBM , etc - similar results just read out for AXL Blocker - Aravive Announces Successful Completion of Phase 1b Trial Evaluating AVB-500 in Platinum Resistant $BRRGF
ECOR - Humira Without Patent Infringement or Common Pharmacologic Adverse Effects.
ECOR - “Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis” -action potentials transmitted in the vagus nerve inhibit the production of tumor necrosis factor (TNF), an inflammatory molecule that is a major therapeutic target in RA. So Gamnacore acts in effect like Humira which is a humanized monoclonal antibody that binds to TNF-aand blocks its interaction with the TNF receptor.” https://www.pnas.org/content/113/29/8284
EIGR ”Although no synthetic IFN-lambda is yet FDA-approved, preliminary results in a clinical trial in hepatitis D patients show that it has the same antiviral potency as type I IFN but is much safer and better tolerated. A study in mice found that synthetic IFN-lambda was as effective as IFN-alpha in treating influenza but didn’t have the same proinflammatory effects.” https://www.google.com/amp/s/www.the-scientist.com/news-opinion/seeking-an-early-covid-19-drug-researchers-look-to-interferons-67753/amp
ECOR Trial “The recruitment began 20th April 2020 and is expected to be complete 31st July 2020” Gammacore for moderate to severe COVID Lung Trial in Spain -Open label -interim Data Soon https://scholar.google.com/scholar?hl=en&as_sdt=0%2C33&as_ylo=2020&q=vagal+stimulus+in+COVID+19&btnG=#d=gs_qabs&u=%23p%3D1TMl9Aeeln4J
ECOR Trial “The recruitment began 20th April 2020 and is expected to be complete 31st July 2020” Gammacore for moderate to severe COVID Lung Trial in Spain -Open label -interim Data Soon https://scholar.google.com/scholar?hl=en&as_sdt=0%2C33&as_ylo=2020&q=vagal+stimulus+in+COVID+19&btnG=#d=gs_qabs&u=%23p%3D1TMl9Aeeln4J
ECOR Presentation Yesterday- ECOR recapped recent events -EUA etc- said they are fully funded through 2022, may pursue ARDS data (in order to expand EUA) and have safety data so good that they may apply for Over the Counter status with the FDA - that was the market moving data IMO - imagine a person worried about exposure to COVID and A bit of Shortness of Breath going to the pharmacy and spending $hundreds to improve breathing by becoming a regular ECOR customer - buying treatment cards at Will? This by all data so far would be safe, effective, And incredibly Lucrative for ECOR.
I agree - ECOR for COVID, CNS, Autoimmune, Psychiatric, & Respiratory to name a few. What household Won’t want one? Especially if OTC?
ECOR -The TSLA of COVID therapy.
ECOR Battery powered COVID Rx- MUSK will want it.
ECOR -Imagine if GILD Remdesivir was OTC! Won’t run out of Electric Charge.
I agree - OTC Anti COVID future is real.